Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia

(2014) D. Rea et al.   HAEMATOLOGICA

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study

(2013) Luciano Levato et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis

(2013) F Gerald R Fowkes et al.   LANCET

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

(2013) T D Kim et al.   LEUKEMIA

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

(2013) F J Giles et al.   LEUKEMIA

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2012) Xuelin Huang et al.   CANCER

Nonatherosclerotic Arterial Disorders of the Lower Extremities

(2012) Ido Weinberg et al.   CIRCULATION

Nilotinib-Associated Vascular Events

(2012) Alfonso Quintás-Cardama et al.   Clinical Lymphoma Myeloma & Leukemia

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

(2012) R A Larson et al.   LEUKEMIA

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

(2011) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)

(2011) et al.   EUROPEAN HEART JOURNAL

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Severe Peripheral Arterial Disease During Nilotinib Therapy

(2011) P. Le Coutre et al.   JNCI-Journal of the National Cancer Institute

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

(2009) A. Quintas-Cardama et al.   BLOOD

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

(2009) S. Branford et al.   BLOOD